Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia

Damato, Valentina; Papi, Claudia; Spagni, Gregorio; Evoli, Amelia; Silvestri, Gabriella; Masi, Gianvito; Sabatelli, Eleonora; Campetella, Lucia; McKeon, Andrew; Andreetta, Francesca; Riso, Vittorio; Monte, Gabriele; Luigetti, Marco; Primiano, Guido; Calabresi, Paolo; Iorio, Raffaele

doi:10.1111/ene.15161

Cited by 12 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acute onset PCD is relatively rare [9]. Currently, relevant scales are being developed to assess the prognosis of patients [10].…”

Section: Discussionmentioning

confidence: 99%

Journal of Multiscale Neuroscience

Wu¹,

Liu²,

Chen³

et al. 2022

J. Multiscale Neurosci.

View full text Add to dashboard Cite

Patients with the major depressive disorder usually manifest with sleep disturbance. Early morning awakening is more closely related to major depressive disorder than other sleep disturbances. This study aimed to assess the effect of early morning awakening in treating patients with major depressive disorder. The eligible patients were divided into two groups according to whether they woke up at 2-4 a.m: early morning awakening and non-early morning awakening group. All patients were assessed using the Hamilton Depression Scale, Hamilton Anxiety Scale, and Repeatable Battery for the Assessment of Neuropsychological Status scores at baseline and the fourth week. Twenty-one men and 31 women (mean age 25.13 ±10.67 years) were enrolled. There was a significant main effect of early morning awakening in the Hamilton Depression Scale (P = 0.04) and Hamilton Anxiety Scale (P = 0.01) at the fourth week after treatment. But there was no significant difference in cognitive changes between the two groups. In conclusion, a major depressive disorder with early morning awakening may result in statistically and clinically significant delay in recovery.

show abstract

“…Acute onset PCD is relatively rare [9]. Currently, relevant scales are being developed to assess the prognosis of patients [10].…”

Section: Discussionmentioning

confidence: 99%

Journal of Multiscale Neuroscience

Wu¹,

Liu²,

Chen³

et al. 2022

J. Multiscale Neurosci.

View full text Add to dashboard Cite

show abstract

“…Most importantly in clinical practice, ACA is a disease for which immunological therapeutic intervention is feasible. In fact, many cases with ACA have reported the efficacy of immunotherapy including prednisolone, IVMP, PE, IVIG, RTX, cyclophosphamide, and other immunosuppressors 7,63,26,40 . In addition, the search for malignancy is mandatory in ACA due to the large proportion of cases with paraneoplastic syndrome, and treatment of the causative tumor should be a priority.…”

Section: Treatment Of Acamentioning

confidence: 99%

Autoimmune cerebellar ataxia

Yaguchi

Kudo

Yabe

2023

Clinical & Exp Neuroim

View full text Add to dashboard Cite

Among the different forms of cerebellar ataxia, autoimmune cerebellar ataxia (ACA) or immune‐mediated cerebellar ataxia (IMCA), which appears to be based on an autoimmune mechanism, has long been considered important from the viewpoint of paraneoplastic syndrome. With the expansion of the concept of immune‐mediated neurological diseases and the identification of many novel autoantibodies, ACA has recently become an important neurological syndrome. Although no definitive diagnostic criteria of ACA exist, Hadjivassilou et al suggested diagnostic criteria for primary ACA in 2020 and Dalmau and Graus showed proposed diagnostic criteria for ACA in 2022. The proposed diagnostic criteria for ACA by Dalmau and Graus emphasize the importance of antibody reliability. In the future, additional studies should be conducted to identify new antibodies associated with ACA and to clarify the importance of each antibody. Moreover, ACA is a disease for which immunological therapeutic intervention is feasible and requires early treatment to maintain cerebellar function. Many cases with ACA have reported the efficacy of immunotherapy. The concept of ACA may have the potential for further expansion and becomes increasingly important in the diagnosis of cerebellar ataxia.

show abstract

Autoimmune Neurobeachin Cerebellar Ataxia

Basal,

Gilligan,

Lesnick

et al. 2024

Movement Disorders

View full text Add to dashboard Cite

BackgroundThere are more than 30 immunoglobulin G (IgG) autoantibody biomarkers of autoimmune cerebellar ataxia reported.ObjectiveTo describe a novel IgG biomarker targeting neurobeachin, a scaffolding protein integral to synapse formation and function.MethodsClinical and laboratory‐based assessment was used for a novel diagnostic biomarker of autoimmune ataxia.ResultsA 46‐year‐old woman had ataxia onset followed by bilateral knee pain, attributable to rheumatoid arthritis. She was negative for standard neural antibodies. Her ataxia stabilized and tremor initially improved after corticosteroid treatment, but she progressed to wheelchair‐dependence (on methotrexate and then rituximab) over 4 years, in keeping with the trajectory encountered by many with autoimmune ataxia. In contrast, her inflammatory arthritis remitted with immunotherapy. Neurobeachin‐IgG was unmasked in serum and cerebrospinal fluid using protein arrays and confirmed using neurobeachin‐specific confocal immunofluorescence and Western blot.ConclusionsNeurobeachin‐IgG is a new neural antibody biomarker of cerebellar ataxia among a growing antibody repertoire, collectively common but often individually rare. © 2024 International Parkinson and Movement Disorder Society.

show abstract

Clinical features and outcome of patients with autoimmune cerebellar ataxia evaluated with the Scale for the Assessment and Rating of Ataxia

Cited by 12 publications

References 23 publications

Journal of Multiscale Neuroscience

Journal of Multiscale Neuroscience

Autoimmune cerebellar ataxia

Autoimmune Neurobeachin Cerebellar Ataxia

Contact Info

Product

Resources

About